Clinical Trials Sponsored by GlaxoSmithKline

Total 4796 results

GlaxoSmithKline

Not yet recruiting

A Study to Evaluate the Safety, Tolerability and Blood Levels of GSK3915393 Administered to Healthy Participants of Chinese, Japanese and European Ancestry and to Assess Effects of GSK3915393 on Nintedanib

Idiopathic Pulmonary Fibrosis
GlaxoSmithKline

Not yet recruiting

Safety, Tolerability and Blood Sampling of GSK3923868 Administered Via Dry Powder Inhaler to Healthy Participants of Chinese, Japanese and European Ancestry

Respiratory Tract Infections

United Kingdom
GlaxoSmithKline

Not yet recruiting

Study to Assess Real-world Effectiveness of Belimumab for Treatment of Adults With LN (OBSErve-LN)

Lupus Nephritis
GlaxoSmithKline

Not yet recruiting

A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer

Melanoma

United States, Germany, Spain, Korea, Republic of, France, Italy, Argentina, Brazil, Denmark, Czechia
GlaxoSmithKline

Not yet recruiting

Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis (ODYSSEY)

Primary Myelofibrosis | Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis
GlaxoSmithKline

Not yet recruiting

Long-Term Study (AtDvance) to Evaluate GSK1070806 in Atopic Dermatitis. (AtDvance)

Dermatitis, Atopic

United States, Germany, Spain, France, Italy, Japan, China, Argentina, Greece, Czechia, Korea, Republic of, Panama, Bulgaria, Canada, Poland, Mexico, Thailand
GlaxoSmithKline

Recruiting

A Study to Investigate the Safety and Pharmacological Effect of a Single Intravenous Infusion of Belantamab in Male and Female Participants Aged 18 to 75 With Moderate to Severe Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

United States
GlaxoSmithKline

Not yet recruiting

Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Patient-derived Organoids and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)

Lung Cancer, Non-Small Cell

United Kingdom
GlaxoSmithKline

Recruiting

A Study to Find and Confirm the Dose and Assess Safety, Reactogenicity and Immune Response of a Vaccine Against Pandemic H5N1 Influenza Virus in Healthy Younger and Older Adults

Influenza, Human

United States
GlaxoSmithKline

Recruiting

A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

Neoplasms

United States, Spain, Korea, Republic of
GlaxoSmithKline

Recruiting

A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma (JADE)

Neoplasms, Head and Neck

United States, Japan, Norway, Spain, Taiwan, United Kingdom, Belgium, Greece, Romania, Sweden, Turkey, Korea, Republic of, China, Argentina, India, Poland, Israel, Portugal, Italy, Germany, Czechia, France, Australia, Hungary, Mexico, Brazil and more
GlaxoSmithKline

Not yet recruiting

A Study on the Immune Response and Safety of a Vaccine Against N. Meningitidis Serogroup B Infection in Healthy Infants From 2 Months of Age

Meningitis, Meningococcal

Korea, Republic of
GlaxoSmithKline

Recruiting

Dose Exploration Study of GSK4532990 in Participants With NASH or Suspected NASH (SKYLINE)

Non-alcoholic Fatty Liver Disease

United States
GlaxoSmithKline

Recruiting

Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Rotarix Porcine Circovirus (PCV)-Free Liquid Compared to Rotarix Liquid Given in 2-doses in Healthy Chinese Infants Starting at Age 6-16 Weeks

Gastroenteritis

China
GlaxoSmithKline

Recruiting

A Dose-Finding Study to Evaluate the Efficacy and Safety of GSK3858279 in Adults With Knee Osteoarthritis Pain (MARS-17)

Pain

France, Japan, Spain, China, Korea, Republic of, United States, Argentina, Canada, Germany, South Africa, Australia, Mexico, United Kingdom
GlaxoSmithKline

Recruiting

Drug Interaction Assessment of GSK3882347 in Healthy Participants Aged 18 to 65 Years

Urinary Tract Infections

United Kingdom
GlaxoSmithKline

Recruiting

A Follow-up Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies During Any Pregnancy Conceived Post Vaccination/Control

Respiratory Syncytial Virus Infections

United States, Australia, Italy, Spain, Belgium, Korea, Republic of, France, Canada, Finland, Taiwan, Thailand, Brazil, India, New Zealand, Germany, South Africa, Colombia, Panama, Philippines, Argentina, Bangladesh, Dominican Republic and more
GlaxoSmithKline

Not yet recruiting

A Pharmacokinetics and Safety Study of Augmentin ES-600 in Children With CAP and ABRS

Infections, Bacterial
GlaxoSmithKline

Recruiting

Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) (OCEAN)

Eosinophilic Granulomatosis With Polyangiitis

Canada, France, Italy, Spain, Belgium, Korea, Republic of, United States, Japan, China, Czechia, Hungary, Israel, Portugal, Poland, Netherlands, United Kingdom, Austria, Argentina, Australia, Brazil, Germany, Sweden
GlaxoSmithKline

Recruiting

Study to Assess Demographic, Pharmacologic, Biomarker, Clinical Features and Quality of Life (QoL) of Participants With Lupus Nephritis

Systemic Lupus Erythematosus

United Arab Emirates
GlaxoSmithKline

Recruiting

Study in Pediatrics With HypEREosinophilic Syndrome (SPHERE) (SPHERE)

Hypereosinophilic Syndrome

United States, Argentina, Spain, Turkey, Israel, Brazil, Mexico, United Kingdom
GlaxoSmithKline

Recruiting

Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma (DREAMM 8)

Multiple Myeloma

China, Korea, Republic of, Australia, Italy, Spain, United States, Brazil, Czechia, France, Germany, Greece, Israel, Japan, New Zealand, Poland, Russian Federation, Turkey, United Kingdom
GlaxoSmithKline

Recruiting

Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma (DREAMM 9)

Multiple Myeloma

Australia, Germany, Italy, Spain, United States, Korea, Republic of, Canada, France, Poland, United Kingdom
GlaxoSmithKline

Active, not recruiting

Study of Subcutaneous (SC) Belimumab in Pediatric Participants With Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus

Netherlands, United States, Germany, Spain, Japan, Argentina, Mexico
GlaxoSmithKline

Active, not recruiting

A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus (RSV) Given to Adults 18 to 49 Years of Age at Increased Risk for Respiratory Syncytial Virus Disease, Compared to Older Adults 60 Years of Age and Above

Respiratory Syncytial Virus Infections

United States, Germany, South Africa, Canada, Japan, Australia
GlaxoSmithKline

Completed

A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone or Co-administered With an Adjuvanted Vaccine Against Influenza in Adults Aged 65 Years and Above

Respiratory Syncytial Virus Infections

France, Finland, Belgium, Spain, United Kingdom
GlaxoSmithKline

Completed

Study to Assess the Immunogenicity and Safety of GSK's Investigational Vaccine (GSK3277511A) When Given to Healthy Smokers and Ex-smokers After Administration of Shingrix Vaccine

Respiratory Disorders

France, Estonia, Spain, Finland, Italy
GlaxoSmithKline

Active, not recruiting

Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2) (B-Well 2)

Chronic Hepatitis B | Hepatitis B, Chronic

United States, Taiwan, Bulgaria, Italy, France, Thailand, Spain, Malaysia, Philippines, China, United Kingdom, Hungary, Korea, Republic of, Romania, Germany, Greece, India, Japan, Panama, Turkey, Poland, Argentina, Australia, Brazil, New... and more
GlaxoSmithKline

Terminated

A Phase III, Double-blind Study to Assess Safety and Efficacy of an RSV Maternal Unadjuvanted Vaccine, in Pregnant Women and Infants Born to Vaccinated Mothers (GRACE)

Respiratory Syncytial Virus Infections

United States, Finland, Taiwan, Spain, Argentina, Philippines, Belgium, Panama, Thailand, France, India, New Zealand, Mexico, Italy, United Kingdom, Korea, Republic of, Bangladesh, Colombia, Dominican Republic, Honduras, South Africa and more
GlaxoSmithKline

Completed

A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 60 Years and Above

Respiratory Syncytial Virus Infections

Panama, New Zealand, South Africa
GlaxoSmithKline

Terminated

Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer

Neoplasms

United States, Korea, Republic of, Canada, Spain, Australia, United Kingdom, France
GlaxoSmithKline

Active, not recruiting

A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody

Multiple Myeloma

United States, Spain, France, United Kingdom, Australia, Italy, Germany, Canada
GlaxoSmithKline

Active, not recruiting

A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With Advanced Solid Tumors

Neoplasms

Spain, Netherlands, United States, Japan, France, Korea, Republic of, Australia, Canada
GlaxoSmithKline

Completed

Belimumab Assessment of Safety in SLE (BASE)

Systemic Lupus Erythematosus

United States, Ukraine, Taiwan, Bulgaria, Canada, Czechia, Estonia, Italy, Poland, Philippines, Korea, Republic of, Romania, Australia, Hong Kong, Portugal, Spain, Thailand, Peru, Argentina, Brazil, Mexico, Hungary, Russian Federation, Malays... and more
GlaxoSmithKline

Active, not recruiting

A Study on the Safety and Immune Response of AS37 Together With Hepatitis B Antigen in Adults Aged 18-45 Years

Hepatitis B

Germany, Belgium, United Kingdom
GlaxoSmithKline

Active, not recruiting

Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN)

Pruritus

United States, France, Spain, Israel, Belgium, Canada, Czechia, Italy, United Kingdom, China, Germany, Mexico, Japan, Brazil, Poland, Russian Federation, Greece, Argentina, Switzerland, Bulgaria
GlaxoSmithKline

Completed

A Mechanistic Study of GSK3228836 With Fine Needle Aspiration (FNA) in Participants With Chronic Hepatitis B (B-Fine)

Hepatitis B

United States, Netherlands, United Kingdom, Canada
GlaxoSmithKline

Active, not recruiting

Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM-3)

Multiple Myeloma

United States, Australia, Spain, Bulgaria, Poland, Belgium, France, Germany, Italy, Hungary, United Kingdom, Greece, Russian Federation, Brazil, China, Korea, Republic of, Japan, Canada, Netherlands
GlaxoSmithKline

Completed

A Study Evaluating Efficacy and Safety of Gepotidacin Compared With Ceftriaxone Plus Azithromycin in the Treatment of Uncomplicated Urogenital Gonorrhea

Gonorrhea

Germany, Spain, Australia, United States, Mexico, United Kingdom
GlaxoSmithKline

Active, not recruiting

A Study on the Immune Response and Safety of an RSV Vaccine When Given to Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant and Are at an Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease and Compared to Healthy Adults 50 Years of Age and Above (RSV OA=ADJ-023)

Respiratory Syncytial Virus Infections

Spain, Japan, Italy, United States, Australia, Canada, Korea, Republic of, Germany
GlaxoSmithKline

Completed

A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults 60 Years of Age and Above

Respiratory Syncytial Virus Infections

Argentina, United States, Germany, Spain, Poland, Canada, Japan, Netherlands
GlaxoSmithKline

Completed

Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age

Malaria

Ghana, Kenya
GlaxoSmithKline

Completed

A Study to Evaluate the Safety and Efficacy of Fluticasone Furoate (FF)/Umeclidinium(UMEC)/Vilanterol (VI) in Participants With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

India
GlaxoSmithKline

Terminated

Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors

Neoplasms

Germany, United States, Netherlands, Canada, Australia, Sweden
GlaxoSmithKline

Completed

Efficacy and Safety of GSK3923868 Inhalation Powder, During Experimental Human Rhinovirus Infection in Participants With Mild Asthma

Pulmonary Disease, Chronic Obstructive

United Kingdom
GlaxoSmithKline

Active, not recruiting

A Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a Targeted Immunotherapy Against HSV in Healthy Participants Aged 18-40 Years or in Participants Aged 18-60 Years With Recurrent Genital Herpes

Herpes Simplex

Germany, United States, Belgium, Canada, Spain, United Kingdom, Estonia, Australia
GlaxoSmithKline

Completed

A Study of Belantamab Mafodotin to Investigate Safety, Tolerability, Pharmacokinetics, Immunogenicity and Clinical Activity in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Multiple Myeloma

China
GlaxoSmithKline

Completed

Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat in Non-Dialysis Subjects Evaluating Hemoglobin (Hgb) and Quality of Life (ASCEND-NHQ)

Anaemia

United States, Canada, France, Russian Federation, Spain, Australia, United Kingdom, Romania, Brazil, Korea, Republic of, Italy, Poland, Argentina, Mexico
GlaxoSmithKline

Active, not recruiting

A Safety and Immune Response Study to Evaluate Varying Doses of an mRNA Vaccine Against Coronavirus Disease 2019 (COVID-19) in Healthy Adults

COVID-19

United States
GlaxoSmithKline

Completed

Long-term Access Program (LAP) of Mepolizumab for Subjects Who Participated in Study MEA115921

Churg-Strauss Syndrome | Eosinophilic Granulomatosis With Polyangiitis

United States, France, Japan, Germany, Canada, United Kingdom, Belgium

3

Subscribe